6533b854fe1ef96bd12ae1a4
RESEARCH PRODUCT
Post-COVID syndrome, inflammation, and diabetes
Ali A. RizviAmita KathuriaWael Al MahmeedKhalid Al-rasadiKamila Al-alawiMaciej BanachYajnavalka BanerjeeAntonio CerielloMustafa CesurFrancesco CosentinoMassimo GaliaSu-yen GohAndrej JanezSanjay KalraPeter KemplerNader LessanPaulo LotufoNikolaos PapanasRaul D. SantosAnca P. StoianPeter P. TothVijay ViswanathanManfredi Rizzosubject
InflammationEndocrinologyCOVID-19 Long COVID New-onset diabetes Newly diagnosed diabetes Post-COVID syndrome SARS CoV-2 Syndemia Type 2 diabetesSARS-CoV-2Endocrinology Diabetes and MetabolismHyperglycemiaInternal MedicineDiabetes MellitusHumansCOVID-19RNA ViralPandemicsdescription
The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-11-01 |